Drug Development

Drug Development AstraZeneca Market Dynamics Sales Performance Pharmaceuticals Tax Law Drug Development Drug Treatments Investment Business Relations

10 ARTICLES

last mo.

AstraZeneca Reports Q1 Growth and Expands US Investments Amid Regulatory Challenges

The pharmaceutical giant posts 10% revenue growth, accelerates US manufacturing and R&D plans, and faces legal scrutiny in China over tax and data issues.

8 ARTICLES

3mo ago

AstraZeneca Announces $2.5 Billion Beijing R&D Hub to Bolster China Presence

3 ARTICLES

4mo ago

Bristol Myers Squibb Predicts 2025 Revenue Decline, Expands Cost-Cutting Measures